fludarabine and pomalidomide

fludarabine has been researched along with pomalidomide in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV	1
Schmidt, C	1

Reviews

1 review(s) available for fludarabine and pomalidomide

Article	Year
Regulatory T cell as a target for cancer therapy. Archivum immunologiae et therapiae experimentalis, 2010, Volume: 58, Issue:3 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine	2010

Other Studies

1 other study(ies) available for fludarabine and pomalidomide

Article	Year
The struggle to do no harm in clinical trials. Nature, 2017, 12-21, Volume: 552, Issue:7685 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine	2017

Article

Year

The struggle to do no harm in clinical trials.

Nature, 2017, 12-21, Volume: 552, Issue:7685

Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine

2017